Results 171 to 180 of about 3,394 (198)
Some of the next articles are maybe not open access.
Letter to the Editor: Midodrine for Hepatic Hydrothorax
Hepatology, 2021We read with interest the article by Banini et al.1 They have succinctly described the pathophysiology and management of hepatic hydrothorax. We would like to share a few thoughts on the management of hepatic hydrothorax.
Anand V. Kulkarni +4 more
openaire +2 more sources
Midodrine in end-stage heart failure [PDF]
BMJ Supportive & Palliative Care, 2020 It is estimated that 5% of patients with heart failure (HF) will progress to end-stage disease refractory to medical therapy and might require prolonged hospitalisation with inotropic support. We present the case of a patient with end-stage HF who was admitted with cardiogenic shock.
Ariel Gonzalez-Cordero +4 more
openaire +2 more sources
Midodrine for the Treatment of Intradialytic Hypotension
Nephron, 1997Recurrent intradialytic hypotension is probably the most severely disabling feature in dialysis patients and the etiology is multifactorial. We assessed the efficacy and safety of midodrine, a selective alpha1-adrenergic pressor agent in 12 patients with recurrent intradialytic hypotension.
Chin-Chin Yang +4 more
openaire +3 more sources
Chest, 2013
Thoracic duct injury is a rare but serious complication following surgery of the neck or chest that leads to uncontrolled chyle leak. Conventional management includes drainage, nutritional modification, or aggressive surgical interventions such as thoracic duct ligation, flap coverage, fibrin glue, or talc pleurodesis; few successful medical ...
Heather Warren +6 more
openaire +3 more sources
Thoracic duct injury is a rare but serious complication following surgery of the neck or chest that leads to uncontrolled chyle leak. Conventional management includes drainage, nutritional modification, or aggressive surgical interventions such as thoracic duct ligation, flap coverage, fibrin glue, or talc pleurodesis; few successful medical ...
Heather Warren +6 more
openaire +3 more sources
Midodrine for the weaning of vasopressor infusions
Journal of Clinical Pharmacy and Therapeutics, 2016Midodrine, an orally available α1-agonist indicated for the treatment of orthostatic hypotension, has been used at our institution as an adjunctive treatment to provide haemodynamic support to facilitate intravenous (IV) vasopressor weaning. Limited published data exist for this off-label use; thus, the objective of this study was to evaluate outcomes ...
L. B. Poveromo +2 more
openaire +3 more sources
Pharmacodynamics of midodrine, an antihypotensive agent
Clinical Pharmacology and Therapeutics, 1986Midodrine is an orally active adrenergic agonist useful in the treatment of hypotension. We have investigated the pharmacodynamics of its active metabolite after oral midodrine therapy in nine patients with severe orthostatic hypotension. Peak plasma levels of the metabolite were reached in 60 to 90 minutes and ranged from 25 to 56 ng/ml.
Prince K. Zachariah +11 more
openaire +3 more sources
Intestinal obstruction associated with oral midodrine
Clinical Autonomic Research, 2004We report a case of severe ileus possibly related to midodrine. To our knowledge, this case report is the first one suggesting an inhibitory effect of midodrine on intestinal motility. The potential pharmacological mechanisms leading to this adverse drug reaction are discussed below.
Michel Galinier +4 more
openaire +3 more sources
Midodrine Hydrochloride in the Treatment of Vasovagal Syncope
Pacing and Clinical Electrophysiology, 1999Therapy of vasovagal syncope is still a subject of debate. Various pharmacotherapies were proposed. However, they are often not tolerated or ineffective. The purpose of this prospective, nonrandomized study was to evaluate the usefulness of alpha‐agonist midodrine hydrochloride in the treatment of vasovagal syncope.
Dusan Trejbal +2 more
openaire +3 more sources
Effects of Promethazine and Midodrine on Orthostatic Tolerance
Aviation, Space, and Environmental Medicine, 2011Astronauts experience both orthostatic hypotension and space motion sickness during re-entry. Midodrine, an alpha1-adrenergic agonist, is used to treat orthostatic hypotension. Promethazine, a histamine H1-receptor antagonist, is prescribed for space motion sickness. Many astronauts need both midodrine and promethazine.
Michael G. Ziegler +3 more
openaire +3 more sources
Midodrine treatment in children with recurrent vasovagal syncope
Cardiology in the Young, 2021AbstractBackground:Vasovagal syncope is the most common cause of syncope in childhood and its treatment is not at a satisfactory level yet. We aimed to investigate patients who were diagnosed with vasovagal syncope, did not benefit from conventional treatment, received midodrine treatment, and to evaluate their response to midodrine treatment.Methods ...
Denizhan Bagrul +4 more
openaire +3 more sources